SOURCE: CLX Investment Company, Inc.

February 27, 2008 11:57 ET

CLX Investment Company Announces New CEO Interview Posted to Company Website

Written Question and Answer Feature Includes Estimate of a $500 Million Potential Market for Zonda's Chlamydia Testing Product

MURRIETA, CA--(Marketwire - February 27, 2008) - CLX Investment Company, Inc. (OTCBB: CLXN), which owns 51% of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets, today announced that Vera Leonard, chief executive officer of Zonda and CLX, has participated in a question and answer feature that has been posted to the CLX website at http://www.clxinvestments.com/othermedia.php. The transcript will also be added to the company's profile on www.equitydigest.com in the coming days.

The question and answer feature includes a detailed discussion by Ms. Leonard of the estimated market potential for Zonda's rapid point of care diagnostic test for chlamydia. CLX and Zonda are currently preparing to initiate clinical trials for the HandiLab-C test for Chlamydia as part of the process to achieve FDA clearance for the product.

Ms. Leonard reviews the fact that chlamydia is now the most frequently reported sexually transmitted disease (STD) in the United States, with more than one million cases reported to the U.S. Centers for Disease Control in 2006. As a result, the CDC has updated its guidelines to recommend that all sexually active females aged 26 or younger be tested annually for chlamydia. With U.S. Census estimates of over 30 million females between the ages of 15 and 29, Ms. Leonard observes that this represents a huge market for chlamydia testing technologies.

Despite the tremendous need, Ms. Leonard continues in the question and answer feature to point out that there is not a technology or testing device currently available that allows doctors to screen patients in a rapid, cost effective and reliable manner. The company's research estimates that as much as 70% of this target population is being missed, which makes the market for the HandiLab-C not only large, but also hugely underserved.

Ms. Leonard also points out that chlamydia testing procedures currently in use require various techniques from heating the specimen for 10 minutes to repeated steps of squeezing and twisting the swab against the side of the test tube. Some products have as many as 11 steps in the testing process. By comparison, the HandiLab-C test for Chlamydia is an enzyme-based technology. There are no antigens to extract. Instead the process is simple, 2-step, self-contained and complete in 15 minutes or less.

Ms. Leonard also discusses the fact that Zonda's chlamydia test is designed to be used in a doctor's office, providing additional incentive for its widespread use. First, there is the advantage that with an almost immediate result, the patient is there to allow the doctor to provide counseling and begin treatment immediately. A lab test can take several days for the test result to be reported. Second, Ms. Leonard points out that when a doctor sends a sample to a laboratory for chlamydia testing, the doctor does not receive the reimbursement from the insurance company -- the lab does. With HandiLab, any reimbursement or payment will be made to the doctor, allowing the doctor to bring greater revenue into his or her practice while utilizing a test that allows the patient to be tested and treated in the same visit.

Ms. Leonard concludes the session with an estimate of the potential U.S. market for the HandiLab-C based on an expected price to patients of $17 - $18 per test. Given the number of females in the age range recommended for testing under CDC guidelines, the potential U.S. market for the test would be in excess of $500 million.

"I was pleased to have this opportunity to address some of the major reasons why CLX has focused its attention on Zonda's chlamydia product," commented Ms. Leonard. "This would be by no means a product of only minor significance in the STD testing market. Given the realities of the growing chlamydia problem in the U.S., particularly the tremendous shortfall in screening for this disease, it is very easy to see how an FDA cleared chlamydia testing product that is simple enough to be used in a doctor's office would likely capture a very large share of the chlamydia testing market."

"I hope this Q & A feature will be helpful for CLX shareholders and provides an understanding of why we are so excited by the potential of Zonda's chlamydia testing product. We expect this to be the first of a series of interviews that will allow me to directly address our motivations and any progress that we can report on the process of launching the HandiLab-C in the U.S. and other worldwide markets," Ms. Leonard added.

To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.

About CLX Investment Company

CLX Investment Company (www.clxinvestments.com) holds a 51% equity interest in Zonda, Inc. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact Information

  • Contacts:
    For CLX Investment Company:
    Gemini Financial Communications
    A. Beyer
    951-677-8073
    Email Contact